Risk Factors and Prediction Model for Liver-Related Outcomes in Elderly Patients With Steatotic Liver Disease
Summary
NIH registered a retrospective cohort study (NCT07537829) on steatotic liver disease in elderly patients. The single-center observational study will analyze approximately 10,000 participants aged 60 and older from the Nanjing Elderly Steatotic Liver Disease Cohort to investigate liver-related and extrahepatic adverse outcomes. Risk prediction models will be developed using machine learning algorithms; no intervention is involved.
What changed
NIH registered a new observational cohort study on ClinicalTrials.gov. The study will retrospectively analyze data from the Nanjing Elderly Steatotic Liver Disease Cohort, including approximately 10,000 participants aged 60+ with steatotic liver disease. Researchers will collect baseline and annual follow-up data on demographics, lifestyle, anthropometric measurements, laboratory tests, abdominal ultrasound, and medication use to investigate risk factors for liver-related outcomes (significant fibrosis, advanced fibrosis, cirrhosis, hepatocellular carcinoma, liver-related death) and extrahepatic outcomes (new-onset type 2 diabetes, chronic kidney disease, cardiovascular disease).
This registry entry does not create compliance obligations for any parties. Healthcare providers and clinical investigators conducting similar research may find this relevant as a reference for cohort study design and endpoints in metabolic dysfunction-associated steatotic liver disease research.
Archived snapshot
Apr 18, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Risk Factors and Prediction Model for Liver-Related Outcomes in Elderly Patients With Steatotic Liver Disease
Observational NCT07537829 Kind: OBSERVATIONAL Apr 17, 2026
Abstract
This is a single-center, retrospective cohort study based on data from the Nanjing Elderly Steatotic Liver Disease Cohort. The study aims to investigate risk factors for liver-related adverse outcomes (including significant fibrosis, advanced fibrosis, cirrhosis, hepatocellular carcinoma, and liver-related death) and extrahepatic outcomes (new-onset type 2 diabetes, chronic kidney disease, and cardiovascular disease) in elderly patients (aged ≥60 years) with steatotic liver disease. A total of approximately 10,000 participants will be included. Baseline and annual follow-up data on demographics, lifestyle, anthropometric measurements, laboratory tests, abdominal ultrasound, and medication use will be collected. Risk prediction models will be developed using machine learning algorithms. The study is observational and does not involve any intervention.
Conditions: Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatotic Liver Disease
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.